Published in BMC Microbiol on March 22, 2013
Antimicrobial Peptide Resistance Mechanisms of Gram-Positive Bacteria. Antibiotics (Basel) (2014) 0.82
Heterogeneity of host TLR2 stimulation by Staphylocoocus aureus isolates. PLoS One (2014) 0.81
Influence of IS256 on genome variability and formation of SCV in Staphylococcus aureus. Antimicrob Agents Chemother (2017) 0.75
The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature (1983) 19.44
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Genetic systems in staphylococci. Methods Enzymol (1991) 9.00
Regulation of cytoplasmic pH in bacteria. Microbiol Rev (1985) 8.45
A vector for systematic gene inactivation in Bacillus subtilis. Microbiology (1998) 8.00
Improved method for electroporation of Staphylococcus aureus. FEMS Microbiol Lett (1992) 6.18
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother (1998) 4.88
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol (1997) 4.52
A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol (2002) 4.26
Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol (2003) 3.89
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother (2000) 3.51
Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev (2004) 3.40
Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun (2000) 3.06
Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol (2003) 2.74
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (1997) 2.61
Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2006) 2.51
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect Immun (2010) 2.33
Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother (2007) 2.33
Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol (2006) 2.32
DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2005) 2.28
Southern hybridization analysis of the mecA deletion from methicillin-resistant Staphylococcus aureus. Biochem Biophys Res Commun (1991) 2.19
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun (2004) 2.14
Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2007) 2.14
Effect of mild acid on gene expression in Staphylococcus aureus. J Bacteriol (2004) 1.96
Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol (2003) 1.92
Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis (1999) 1.87
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2009) 1.75
CodY in Staphylococcus aureus: a regulatory link between metabolism and virulence gene expression. J Bacteriol (2009) 1.68
Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun (2000) 1.68
Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother (2003) 1.67
tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.64
Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl Acad Sci U S A (2001) 1.64
Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology (2008) 1.62
An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.57
Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int J Med Microbiol (2007) 1.57
Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Infect Immun (2002) 1.49
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol (2008) 1.46
Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog (2012) 1.44
Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol (2011) 1.32
Characterization of the Staphylococcus aureus CidR regulon: elucidation of a novel role for acetoin metabolism in cell death and lysis. Mol Microbiol (2006) 1.32
walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother (2011) 1.27
Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother (2011) 1.27
Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2012) 1.27
Genetic analysis of the cap5 locus of Staphylococcus aureus. FEMS Microbiol Lett (1999) 1.22
Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus. Infect Immun (1987) 1.22
Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Antimicrob Agents Chemother (2006) 1.18
Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus. J Bacteriol (1999) 1.08
Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance. Antimicrob Agents Chemother (2009) 1.07
Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol (2009) 1.05
Staphylococcus aureus strain designation by agr and cap polymorphism typing and delineation of agr diversification by sequence analysis. Int J Med Microbiol (2005) 1.00
UDP-acetyl-mannosamine dehydrogenase is an endogenous protein substrate of Staphylococcus aureus protein-tyrosine kinase activity. J Mol Microbiol Biotechnol (2007) 0.96
Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. Antimicrob Agents Chemother (2006) 0.96
Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother (2006) 0.95
The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.92
A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Antimicrob Agents Chemother (2012) 0.91
Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Hum Vaccin (2009) 0.89
Tracking changes in the vraSR and graSR two component regulatory systems during the development and loss of vancomycin non-susceptibility in a clinical isolate. Clin Microbiol Infect (2011) 0.79
Susceptibility of capsular Staphylococcus aureus strains to some antibiotics, triclosan and cationic biocides. J Antimicrob Chemother (2004) 0.76
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev (2004) 3.40
Whole-genome sequencing of staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J Bacteriol (2005) 3.28
Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis (2008) 2.41
Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance. Antimicrob Agents Chemother (2006) 1.99
Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog (2007) 1.92
Biofilm formation, icaADBC transcription, and polysaccharide intercellular adhesin synthesis by staphylococci in a device-related infection model. Infect Immun (2005) 1.78
Influence of the two-component system SaeRS on global gene expression in two different Staphylococcus aureus strains. J Bacteriol (2006) 1.76
CodY in Staphylococcus aureus: a regulatory link between metabolism and virulence gene expression. J Bacteriol (2009) 1.68
Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother (2003) 1.67
Molecular architecture of the regulatory Locus sae of Staphylococcus aureus and its impact on expression of virulence factors. J Bacteriol (2003) 1.67
Import and spread of Panton-Valentine Leukocidin-positive Staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis (2011) 1.67
Transcription of the phage-encoded Panton-Valentine leukocidin of Staphylococcus aureus is dependent on the phage life-cycle and on the host background. Microbiology (2009) 1.66
Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun (2005) 1.62
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol (2006) 1.62
Role of Staphylococcus aureus global regulators sae and sigmaB in virulence gene expression during device-related infection. Infect Immun (2005) 1.61
Diversity of prophages in dominant Staphylococcus aureus clonal lineages. J Bacteriol (2009) 1.61
The virulence regulator Sae of Staphylococcus aureus: promoter activities and response to phagocytosis-related signals. J Bacteriol (2008) 1.58
Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int J Med Microbiol (2007) 1.57
IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. J Immunol (2008) 1.53
Extensive phage dynamics in Staphylococcus aureus contributes to adaptation to the human host during infection. Mol Microbiol (2006) 1.52
Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun (2006) 1.51
Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.51
Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Infect Immun (2002) 1.49
CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A (2006) 1.49
Differential target gene activation by the Staphylococcus aureus two-component system saeRS. J Bacteriol (2009) 1.49
Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int J Med Microbiol (2003) 1.48
NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol (2008) 1.47
Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents (2008) 1.46
The stringent response of Staphylococcus aureus and its impact on survival after phagocytosis through the induction of intracellular PSMs expression. PLoS Pathog (2012) 1.46
Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis (2004) 1.40
Staphylococcus aureus CcpA affects biofilm formation. Infect Immun (2008) 1.37
Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother (2004) 1.35
Analysis of the matrix-assisted laser desorption ionization-time of flight mass spectrum of Staphylococcus aureus identifies mutations that allow differentiation of the main clonal lineages. J Clin Microbiol (2013) 1.34
Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect Immun (2002) 1.32
Staphylococcus aureus determinants for nasal colonization. Trends Microbiol (2012) 1.31
Suicidal erythrocyte death in sepsis. J Mol Med (Berl) (2006) 1.30
Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J Infect Dis (2010) 1.30
Role of the (p)ppGpp synthase RSH, a RelA/SpoT homolog, in stringent response and virulence of Staphylococcus aureus. Infect Immun (2010) 1.29
sae is essential for expression of the staphylococcal adhesins Eap and Emp. Microbiology (2005) 1.27
Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol (2009) 1.25
Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am (2009) 1.25
NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J Biol Chem (2003) 1.25
An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.24
Regulatory and genomic plasticity of Staphylococcus aureus during persistent colonization and infection. Int J Med Microbiol (2004) 1.23
The CodY pleiotropic repressor controls virulence in gram-positive pathogens. FEMS Immunol Med Microbiol (2011) 1.20
Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl Environ Microbiol (2003) 1.20
Regulatory adaptation of Staphylococcus aureus during nasal colonization of humans. PLoS One (2010) 1.19
High phenotypic diversity in infecting but not in colonizing Staphylococcus aureus populations. Environ Microbiol (2007) 1.17
Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol Microbiol (2006) 1.15
Wall teichoic Acid-dependent adsorption of staphylococcal siphovirus and myovirus. J Bacteriol (2011) 1.15
Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by Staphylococcus aureus. Infect Immun (2008) 1.15
The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes (2005) 1.15
Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One (2009) 1.14
sigmaB and the sigmaB-dependent arlRS and yabJ-spoVG loci affect capsule formation in Staphylococcus aureus. Infect Immun (2007) 1.12
Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob Agents Chemother (2011) 1.12
The staphylococcal respiratory response regulator SrrAB induces ica gene transcription and polysaccharide intercellular adhesin expression, protecting Staphylococcus aureus from neutrophil killing under anaerobic growth conditions. Mol Microbiol (2007) 1.10
A point mutation in the sensor histidine kinase SaeS of Staphylococcus aureus strain Newman alters the response to biocide exposure. J Bacteriol (2009) 1.10
Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun (2008) 1.10
Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus. J Clin Microbiol (2010) 1.08
Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int J Med Microbiol (2010) 1.08
Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation. Int J Med Microbiol (2013) 1.08
Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity. Appl Environ Microbiol (2002) 1.07
Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance. Antimicrob Agents Chemother (2009) 1.07
Cytoplasmic replication of Staphylococcus aureus upon phagosomal escape triggered by phenol-soluble modulin α. Cell Microbiol (2013) 1.06
Mode of action of human beta-defensin 3 against Staphylococcus aureus and transcriptional analysis of responses to defensin challenge. Int J Med Microbiol (2008) 1.05
Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol (2009) 1.05
RNase Y of Staphylococcus aureus and its role in the activation of virulence genes. Mol Microbiol (2012) 1.05
Two small (p)ppGpp synthases in Staphylococcus aureus mediate tolerance against cell envelope stress conditions. J Bacteriol (2013) 1.04
The synthesis and function of the alarmone (p)ppGpp in firmicutes. Int J Med Microbiol (2009) 1.04
Global analysis of the Staphylococcus aureus response to mupirocin. Antimicrob Agents Chemother (2011) 1.04
Multilocus PCR typing strategy for differentiation of Staphylococcus aureus siphoviruses reflecting their modular genome structure. Environ Microbiol (2010) 1.02
Evaluation of intraspecies interference due to agr polymorphism in Staphylococcus aureus during infection and colonization. J Infect Dis (2003) 1.01
Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog (2012) 1.01
Influence of ciprofloxacin and vancomycin on mutation rate and transposition of IS256 in Staphylococcus aureus. Int J Med Microbiol (2010) 1.00
Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis (2013) 1.00